Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/29523108/ below:

Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial

Randomized Controlled Trial

Affiliations

• ¹ Department of Public Health Programmes, Randers Regional Hospital, Skovlyvej 15, 8930, Randers, NØ, Denmark. mettrani@rm.dk.
• ² Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 82, 8200, Aarhus N, Denmark. mettrani@rm.dk.
• ³ Department of Public Health, Section for Epidemiology, Aarhus University, Bartholins Allé 2, 8000, Aarhus C, Denmark.
• ⁴ Department of Obstetrics and Gynecology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark.
• ⁵ Department of Clinical Medicine, University of Southern Denmark, J.B. Winslows Vej 25, 5000, Odense C, Denmark.
• ⁶ Statens Serum Institut, 2300, Copenhagen S, Artillerivej 5, Denmark.
• ⁷ Department of Public Health Programmes, Randers Regional Hospital, Skovlyvej 15, 8930, Randers, NØ, Denmark.
• ⁸ Department of Pathology, Randers Regional Hospital, Østervangsvej 48, 8930, Randers, NØ, Denmark.
• ⁹ Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 82, 8200, Aarhus N, Denmark.

• PMID: 29523108
• PMCID: PMC5845195
• DOI: 10.1186/s12885-018-4165-4

Item in Clipboard

Randomized Controlled Trial

Mette Tranberg et al. BMC Cancer. 2018.

• ¹ Department of Public Health Programmes, Randers Regional Hospital, Skovlyvej 15, 8930, Randers, NØ, Denmark. mettrani@rm.dk.
• ² Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 82, 8200, Aarhus N, Denmark. mettrani@rm.dk.
• ³ Department of Public Health, Section for Epidemiology, Aarhus University, Bartholins Allé 2, 8000, Aarhus C, Denmark.
• ⁴ Department of Obstetrics and Gynecology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark.
• ⁵ Department of Clinical Medicine, University of Southern Denmark, J.B. Winslows Vej 25, 5000, Odense C, Denmark.
• ⁶ Statens Serum Institut, 2300, Copenhagen S, Artillerivej 5, Denmark.
• ⁷ Department of Public Health Programmes, Randers Regional Hospital, Skovlyvej 15, 8930, Randers, NØ, Denmark.
• ⁸ Department of Pathology, Randers Regional Hospital, Østervangsvej 48, 8930, Randers, NØ, Denmark.
• ⁹ Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 82, 8200, Aarhus N, Denmark.

• PMID: 29523108
• PMCID: PMC5845195
• DOI: 10.1186/s12885-018-4165-4

Item in Clipboard

Background: Cervical cancer screening participation remains insufficient in most countries. Our aim was to evaluate whether offering a HPV self-sampling kit, either mailed directly to the woman's home or using timely opt-in procedures for ordering the kit, increased screening participation compared with a standard second reminder.

Methods: In this randomized, controlled effectiveness trial, 9791 Danish women aged 30-64 who were due to receive the second reminder were equally randomized to either: 1) direct mailing of a second reminder and a self-sampling kit (directly mailed group); 2) mailing of a second reminder that offered a self-sampling kit to be ordered by e-mail, text message, phone, or webpage (opt-in group); or 3) mailing of a second reminder to attend regular cytology screening (control group). In an intention-to-treat analysis, we estimated the participation rate at 180 days post intervention, by returning a self-sample or attending regular cytology screening. We calculated the proportion of women with a positive HPV self-sample who attended for cervical cytology triage at the general practitioner within 90 days.

Results: Participation was significantly higher in the directly mailed group (38.0%) and in the opt-in group (30.9%) than in the control group (25.2%) (participation difference (PD): 12.8%, 95% CI: 10.6-15.0% and PD: 5.7%, 95% CI: 3.5-7.9%, respectively). Within 90 days, 107 women (90.7%, 95% CI: 83.9-95.3%) with a HPV-positive self-sample attended follow-up.

Conclusions: Offering the opportunity of HPV self-sampling as an alternative to regular cytology screening increased participation; the direct mailing strategy was the most effective invitation strategy. A high compliance with follow-up was seen.

Trial registration: Current Controlled Trials NCT02680262 . Registered 10 February 2016.

Keywords: Cancer prevention; Cervical cancer screening; Human papillomavirus testing; Screening participation; Self-sampling.

PubMed Disclaimer

The study was approved by the Danish Data Protection Agency (j.no: 1–16–02-495-15) and by the Danish Health Authorities (j.no: 3–3013-1407/1). Furthermore, the study achieved clearance at the Central Denmark Region Committees on Health Research Ethics (j.no: 1–10–72-259-15). The included women were informed that if they returned their self-sample they thereby expressed their consent to participate in the study.

Not applicable.

Axlab, the Danish manufacturer of Evalyn® Brush, and Roche, the manufacturer of the Cobas® 4800 HPV DNA assay, provided self-sampling devices and test kits for the study. According to the contract between the manufacturers and the Department of Public Health Programmes, Randers Regional Hospital, Axlab and Roche had no influence on the scientific process and no editorial rights pertaining to this manuscript. The authors retained the right to submit the manuscript. None of the authors were compensated for their work on this study, have any shares in the manufacturers’ companies, or received bonuses from any of the manufacturers. All authors declare no conflicts of interest.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Flow chart of the study…

Flow chart of the study design. Abbreviations: HPV self-sampling: HPV SS. GP: General…

Flow chart of the study design. Abbreviations: HPV self-sampling: HPV SS. GP: General Practitioner.*) Also had the possibility of attending a GP for regular cytology screening

• Study protocol of the CHOiCE trial: a three-armed, randomized, controlled trial of home-based HPV self-sampling for non-participants in an organized cervical cancer screening program.

  Tranberg M, Bech BH, Blaakær J, Jensen JS, Svanholm H, Andersen B. Tranberg M, et al. BMC Cancer. 2016 Nov 3;16(1):835. doi: 10.1186/s12885-016-2859-z. BMC Cancer. 2016. PMID: 27809810 Free PMC article. Clinical Trial.

• Participation and relative cost of attendance by direct-mail compared to opt-in invitation strategy for HPV self-sampling targeting cervical screening non-attenders: A large-scale, randomized, pragmatic study.

  Pedersen BT, Sonne SB, Pedersen H, Andreasen EK, Serizawa R, Ejegod DM, Bonde J. Pedersen BT, et al. Int J Cancer. 2025 Apr 15;156(8):1594-1605. doi: 10.1002/ijc.35263. Epub 2024 Nov 23. Int J Cancer. 2025. PMID: 39579017 Free PMC article. Clinical Trial.

• Comparison of two invitation-based methods for human papillomavirus (HPV) self-sampling with usual care among un- and under-screened Māori, Pacific and Asian women: study protocol for a randomised controlled community trial to examine the effect of self-sampling on participation in cervical-cancer screening.

  Brewer N, Bartholomew K, Maxwell A, Grant J, McPherson G, Wihongi H, Bromhead C, Scott N, Crengle S, Cunningham C, Douwes J, Potter JD. Brewer N, et al. BMC Cancer. 2019 Dec 9;19(1):1198. doi: 10.1186/s12885-019-6401-y. BMC Cancer. 2019. PMID: 31815615 Free PMC article.

• High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening.

  Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R, van Kemenade FJ, Heideman DA, Meijer CJ. Snijders PJ, et al. Int J Cancer. 2013 May 15;132(10):2223-36. doi: 10.1002/ijc.27790. Epub 2012 Sep 14. Int J Cancer. 2013. PMID: 22907569 Review.

• Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials.

  Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJ, Arbyn M. Verdoodt F, et al. Eur J Cancer. 2015 Nov;51(16):2375-85. doi: 10.1016/j.ejca.2015.07.006. Epub 2015 Aug 18. Eur J Cancer. 2015. PMID: 26296294 Review.

• Promotion of Cervical Screening among Long-term Non-attendees by Human Papillomavirus Self-sampling.

  Ernstson A, Forslund O, Borgfeldt C. Ernstson A, et al. J Cancer Prev. 2021 Mar 30;26(1):25-31. doi: 10.15430/JCP.2021.26.1.25. J Cancer Prev. 2021. PMID: 33842403 Free PMC article.

• Investigating the decrease in participation in the Dutch cervical cancer screening programme: The role of personal and organisational characteristics.

  Aitken CA, Kaljouw S, Siebers AG, Bron M, Morssink A, van Kemenade FJ, de Kok IMCM. Aitken CA, et al. Prev Med Rep. 2021 Feb 20;22:101328. doi: 10.1016/j.pmedr.2021.101328. eCollection 2021 Jun. Prev Med Rep. 2021. PMID: 33680719 Free PMC article.

• Evaluating Opt-In Vaginal Human Papillomavirus Self-Sampling: Participation Rates and Detection of High-Grade Lesions (CIN2+) among Unscreened Japanese Women Aged 30-39.

  Taro I, Onuma T, Kurokawa T, Chino Y, Shinagawa A, Yoshida Y. Taro I, et al. Healthcare (Basel). 2024 Mar 6;12(5):599. doi: 10.3390/healthcare12050599. Healthcare (Basel). 2024. PMID: 38470710 Free PMC article.

• Expanding the upper age limit for cervical cancer screening: a protocol for a nationwide non-randomised intervention study.

  Tranberg M, Petersen LK, Elfström KM, Hammer A, Blaakær J, Bennetsen MH, Jensen JS, Andersen B. Tranberg M, et al. BMJ Open. 2020 Nov 5;10(11):e039636. doi: 10.1136/bmjopen-2020-039636. BMJ Open. 2020. PMID: 33154056 Free PMC article.

• Increasing coverage in cervical and colorectal cancer screening by leveraging attendance at breast cancer screening: A cluster-randomised, crossover trial.

  Helgestad ADL, Larsen MB, Njor S, Tranberg M, Petersen LK, Andersen B. Helgestad ADL, et al. PLoS Med. 2024 Aug 13;21(8):e1004431. doi: 10.1371/journal.pmed.1004431. eCollection 2024 Aug. PLoS Med. 2024. PMID: 39137185 Free PMC article. Clinical Trial.

1. 1. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009;45(15):2640–2648. doi: 10.1016/j.ejca.2009.07.018. - DOI - PubMed
2. 1. Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L, Strander B, Ryd W, Dillner J, Tornberg S, Sparen P. Screening and cervical cancer cure: population based cohort study. BMJ. 2012;344:e900. doi: 10.1136/bmj.e900. - DOI - PMC - PubMed
3. 1. Vaccarella S, Franceschi S, Engholm G, Lönnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014;111(5):965–969. doi: 10.1038/bjc.2014.362. - DOI - PMC - PubMed
4. 1. Advisory Committee Recommendations on cancer screening in the European union. Advisory committee on cancer prevention. Eur J Cancer. 2000;36(12):1473–1478. doi: 10.1016/S0959-8049(00)00122-2. - DOI - PubMed
5. 1. Bosgraaf RP, Siebers AG, De Hullu JA, Massuger LF, Bulten J, Bekkers RL, Melchers WJ. The current position and the future perspectives of cervical cancer screening. Expert Rev Anticancer Ther. 2014;14(1):75–92. doi: 10.1586/14737140.2014.856273. - DOI - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3